Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway
Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation. We hypothesized that pre-treatment of glioblastoma with bortezomib (BTZ) mig...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2022-12-01
|
| coleção: | Frontiers in Cell and Developmental Biology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fcell.2022.1022191/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|